Ana Luzuriaga: Targeting Rare Diseases
Pfizer Spain Communication Manager fights for better understanding, treatments, and policy support for rare diseases
Tobias Schulz: Health Data
Pfizer Germany Senior Manager, Policy and Public Affairs, built a career on making sure that health data is used in the best ways it can be for patients and society
Bharati Shivalkar: Women at Heart
Pfizer’s BeLux Country Medical Director is passionate about fighting cardiovascular disease and empowering women
Isabella Grueso: Beating Cancer
Pfizer’s Global Breast Cancer & Precision Medicine Policy Director grew up seeing the importance of Access to Medicines, and applies these lessons to breast cancer policy today
Jo Atkinson: Fighting Resistant Infections
Pfizer’s Anti-Infectives Product Lead highlights the importance of R&D with a focus on AMR patients.

Meet the Team
EU Register of Interest Representatives # 4263301811-33
May 31
Ana's daughter was diagnosed with Potocki-Lupski syndrome, a rare disorder that affects children's growth.
Today, she works to ensure a better future for #RareDisease patients. 👇
#LivingInnovation #EUPharmaStrategy
May 30
We would like to thank all the participants of Pfizer's 5th Annual Global AMR Patient Summit of last week.
The patient voice is critical for #AMR to stay on top of the political agenda in the EU and globally.
#LivingInnovation https://t.co/AJgok9aHBF

May 30
The Medtech Forum begins today! @medtecheurope
Looking forward to the discussions about #EHDS and how the use of real-world data can improve research and innovation.
https://t.co/Gi5drUGl7P #LivingInnovation https://t.co/q7JzX1XPm2

May 26
🤔 Have you kept track of all the ground-breaking advances in medical technology? Or new ones coming in the near future?
#AI and data tech offer incredible benefits 👇
https://t.co/CvLTvZy2jm #LivingInnovation #EHDS https://t.co/AVL4DD1AcY

May 25
RT @Vision4Health: Health systems must be better connected: to avoid fragmentation, we need to define common specifications for infrastructure and standardised requirements for #data processing at an early stage. Read ...
https://twitter.com/PfizerEUPolicy/status/1661721908671311872

May 25
Today, 🇪🇺 Cancer Week begins. #EWAC
"Cancer patients facing delays of more than two years for new medicines in countries like Malta and Bulgaria do not have the luxury of waiting around for lengthy and unpredictable legislative developments."
- @NathalieMoll
#LivingInnovation https://t.co/EX0xMoVFlr

May 23
We are excited to host Pfizer's 5th Annual Global AMR Patient Summit tomorrow in Brussels.
Tackling #AMR is crucial to public health and only by partnering with patient advocacy groups we can make the difference.
#LivingInnovation https://t.co/eiUvM4gjIU

May 22
Diagnosing rare diseases is complex and often takes time.
#PfizerColleague Ana Luzuriaga, whose daughter suffers from a #RareDisease, had to wait more than 2 years to get a diagnosis.
This is her #LivingInnovation story ⬇️
https://t.co/TyyBBShiQl https://t.co/uIyDPJj4vV

May 19
Tomorrow is #ClinicalTrialsDay. A celebration of the 1st clinical trial that took place more than 250 years ago.
They are the backbone of medicine development: scientists, researchers, clinicians and patients behind these studies truly make our world healthier. #LivingInnovation https://t.co/2jH1U7BuCH

May 18
Today is #WorldAidsVaccineDay.
While progress has been made, the disease cannot be eradicated without an effective vaccine.
For this, a strong EU R&D ecosystem is key. Weakening incentives will negatively impact investment & innovation.
#LivingInnovation #EUPharmaStrategy